Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients | ||||
Medical Journal of Viral Hepatitis | ||||
Article 5, Volume 7.1, Issue 1, December 2022, Page 21-32 PDF (583.69 K) | ||||
Document Type: Original article | ||||
DOI: 10.21608/mjvh.2022.279334 | ||||
View on SCiNiTO | ||||
Authors | ||||
Ali Nada1; Lmyaa Ata1; Amany A. Amer2; Naglaa S. Elabd 2 | ||||
1Hepatology Gastroenterology Department, National liver institute, Menoufia University, Menoufia, Egypt | ||||
2Tropical Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt | ||||
Abstract | ||||
Background: Hepatitis C virus (HCV) treatment aims to halt the progression of fibrosis and reducing its complications. HCV-treatment has been enhanced by the development of all-oral DAAs with good efficacy and a reasonable side effect. Aims: The goal of this study is to see how long-term eradication of HCV affect liver fibrosis following DAAs therapy. Materials and methods: 500 HCV patients receiving sofosbuvir-based therapy with daclatasvir or ledipasvir (with or without ribavirin). In addition to clinical, laboratory, and radiological examination, FIB-4, APRI, Fibroscan examination, Child and MELD scores were calculated at baseline and one year after end of therapy (EOT). Results: Out of 500 participants included in the study, 493 participants complete the study period. 454 (92.1%) patients had sustained virologic response (SVR) during the period of study and 39 patients were non-responders. In patients with SVR, FIB-4 index, APRI score and fibroScan measures showed significant reduction one-year post-EOT versus baseline (p < 0.001 for all). Although, Child score in patients had SVR did not demonstrate a significant improvement one year after EOT versus baseline (p = 0.479), it showed a significant improvement versus non responder (p < 0.001). In addition, MELD score revealed a significant reduction in patients who achieved SVR one-year post-EOT versus baseline (p = 0.028). Furthermore, one-year following EOT, there was a significant improvement in MELD score in patients with SVR versus non-responder (p < 0.001). Conclusion: DAAs therapy in HCV-related liver disease had a good impact on liver fibrosis regression and the improvement of its outcome. | ||||
Keywords | ||||
Child score; DAAs therapy; HCV; Liver fibrosis parameters; MELD | ||||
Statistics Article View: 158 PDF Download: 254 |
||||